VTGN

Vistagen Therapeutics Inc

Oct 17 • 04:00PM ET

4.05

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB NBIX ALNY ONC ACAD CORT EDIT FATE AUPH MDGL

| Held by: VTI PSIL VXF IWC AVSC DCOR DXUV

Index	-	P/E	-	EPS (ttm)	-1.58	Insider Own	9.63%	Shs Outstand	29.28M	Perf Week	0.50%
Market Cap	124.26M	Forward P/E	-	EPS next Y	-1.66	Insider Trans	0.00%	Shs Float	27.73M	Perf Month	33.22%
Enterprise Value	63.44M	PEG	-	EPS next Q	-0.48	Inst Own	55.81%	Short Float	4.85%	Perf Quarter	58.82%
Income	-47.30M	P/S	177.51	EPS this Y	2.99%	Inst Trans	14.16%	Short Ratio	2.39	Perf Half Y	91.94%
Sales	0.70M	P/B	2.09	EPS next Y	-2.47%	ROA	-42.35%	Short Interest	1.34M	Perf YTD	37.29%
Book/sh	1.94	P/C	1.97	EPS next 5Y	17.83%	ROE	-46.28%	52W High	4.39 -7.74%	Perf Year	38.70%
Cash/sh	2.06	P/FCF	-	EPS past 3/5Y	39.12% 35.63%	ROIC	-82.20%	52W Low	1.90 113.16%	Perf 3Y	8.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-24.04% -	Gross Margin	11.86%	Volatility	6.78% 7.65%	Perf 5Y	-82.05%
Dividend TTM	-	EV/Sales	90.63	EPS Y/Y TTM	54.91%	Oper. Margin	-7566.52%	ATR (14)	0.27	Perf 10Y	-98.77%
Dividend Ex-Date	-	Quick Ratio	5.98	Sales Y/Y TTM	-33.00%	Profit Margin	-6774.22%	RSI (14)	64.59	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.98	EPS Q/Q	-34.18%	SMA20	7.77%	Beta	0.53	Target Price	14.50
Payout	-	Debt/Eq	0.04	Sales Q/Q	23.67%	SMA50	17.86%	Rel Volume	0.67	Prev Close	4.05
Employees	57	LT Debt/Eq	0.01	Earnings	Aug 07 AMC	SMA200	45.76%	Avg Volume	563.11K	Price	4.05
IPO	Jun 21, 2011	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.70% -62.29%	Trades		Volume	375,217	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy	$15
Aug-07-23	Upgrade	Maxim Group	Hold → Buy	$30
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	Jefferies	Buy → Hold
May-20-21	Initiated	Robert W. Baird	Outperform	$9
Feb-18-21	Initiated	Jefferies	Buy	$6
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy	$6
Feb-08-18	Reiterated	Chardan Capital Markets	Buy	$30 → $22
Mar-28-17	Initiated	Maxim Group	Buy	$4

Show Previous Ratings

Oct-16-25 08:30AM	Vistagen to Present at The Menopause Society 2025 Annual Meeting (Business Wire)
Sep-26-25 02:30PM	Janus Henderson Just Took a 13.6% Stake in Vistagen. Should You Buy VTGN Stock Now? (Barchart)
Sep-09-25 08:30AM	Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Business Wire)
Sep-02-25 03:51AM	Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial (Insider Monkey) +5.39%
Aug-08-25 09:02AM	Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ... (GuruFocus.com) +8.79%
07:20PM	Loading…
Aug-07-25 07:20PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.08%
04:30PM	Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update (Business Wire)
Aug-06-25 06:15PM	Exact Sciences (EXAS) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 10:00AM	Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-25 08:30AM	Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 (Business Wire)
Jul-24-25 08:30AM	Vistagen to Present at the BTIG Virtual Biotechnology Conference (Business Wire)
Jul-15-25 08:30AM	Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership (Business Wire) -5.46%
Jul-02-25 10:03PM	Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay (Insider Monkey)
Jun-25-25 08:30AM	Vistagen Appoints Elissa Cote as Chief Corporate Development Officer (Business Wire)
Jun-18-25 03:01AM	Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com) -13.45%
04:30PM	Loading…
Jun-17-25 04:30PM	Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update (Business Wire)
05:20AM	Results season slows to a dribble (MarketWatch)
04:11AM	Stock Market Today: Dow, S&P 500 and Nasdaq marked lower as Trump says to 'evacuate Tehran' with Fed decision, retail sales on tap (MarketWatch)
Jun-16-25 09:16AM	Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For (GuruFocus.com) +6.79%
Jun-12-25 08:30AM	Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 (Business Wire)
Jun-02-25 08:30AM	Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year (Business Wire) -6.01%
May-28-25 08:30AM	Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York (Business Wire)
May-23-25 08:30AM	Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference (Business Wire)
May-15-25 09:15AM	Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-14-25 05:35PM	Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-13-25 05:15PM	Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-17-25 08:30AM	Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference (Business Wire)
Mar-19-25 08:30AM	Vistagen to Present at the 2025 Anxiety and Depression Association Conference (Business Wire)
Mar-04-25 08:30AM	Vistagen to Participate in Stifel 2025 Virtual CNS Forum (Business Wire) +6.43%
08:30AM	Loading…
Feb-20-25 08:30AM	Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference (Business Wire)
Feb-14-25 02:22AM	Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... (GuruFocus.com)
Feb-13-25 05:55PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:30PM	Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update (Business Wire)
Feb-12-25 07:51AM	Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result (GuruFocus.com)
Feb-06-25 08:30AM	Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 (Business Wire)
Feb-05-25 08:30AM	Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Jan-15-25 05:16AM	Vistagen reports positive outcomes from Phase IIA cancer cachexia trial (Clinical Trials Arena)
Jan-14-25 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia (Business Wire)
Jan-10-25 08:30AM	Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Nov-14-24 08:30AM	Vistagen to Present at the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 02:31AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... (GuruFocus.com)
Nov-07-24 07:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Business Wire)
Nov-06-24 07:51AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Nov-05-24 08:30AM	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Business Wire)
Nov-01-24 08:30AM	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Business Wire)
Oct-11-24 12:00PM	VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-09-24 06:20PM	Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
08:30AM	Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day (Business Wire)
Sep-24-24 04:52AM	Vistagen enrols first subject in Phase III trial of social anxiety disorder drug (Clinical Trials Arena)
Sep-23-24 08:30AM	Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Sep-06-24 12:00PM	All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update (Business Wire)
Aug-06-24 08:30AM	Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 (Business Wire)
Jul-26-24 06:20AM	3 Stocks Under $15 That Could Make You a Millionaire (InvestorPlace)
Jul-10-24 06:33AM	Vistagen secures new patents for PH80 migraine treatment (Pharmaceutical Technology)
Jul-09-24 08:30AM	Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine (Business Wire) +5.90%
Jun-27-24 08:30AM	Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year (Business Wire) +7.08%
Jun-12-24 08:52AM	VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:02AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-11-24 04:20PM	Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
Jun-07-24 08:30AM	Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 (Business Wire)
May-29-24 08:30AM	Vistagen to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-24 08:30AM	Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference (Business Wire)
May-14-24 06:59AM	3 Must-Have Penny Stocks to Boost Your 2024 Portfolio (InvestorPlace)
May-13-24 10:00AM	Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence (InvestorPlace)
May-07-24 08:30AM	Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-25-24 08:30AM	Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue (Business Wire)
Apr-19-24 07:13AM	7 Stocks Under $15 Predicted to Boom in the Next 2 Years (InvestorPlace)
Apr-09-24 01:28PM	Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 (InvestorPlace)
08:30AM	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Business Wire)
Apr-01-24 08:30AM	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Business Wire)
Mar-31-24 10:00AM	Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027 (InvestorPlace)
Mar-26-24 06:24AM	30 Countries with the Lowest Depression Rates (Insider Monkey)
Mar-11-24 08:30AM	Vistagen to Present at Stifel 2024 Virtual CNS Days (Business Wire)
Feb-28-24 08:30AM	Vistagen to Present at TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-21-24 09:55AM	Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect? (Zacks)
Feb-19-24 12:24PM	3 Revolutionary Biotech Stocks Poised for 10X Surge (InvestorPlace)
Feb-15-24 08:20AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript (Insider Monkey)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.00%
Feb-13-24 04:59PM	Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ... (GuruFocus.com)
04:20PM	Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update (Business Wire)
Feb-07-24 07:38AM	3 Penny Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Feb-06-24 08:30AM	Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 (Business Wire)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Dec-29-23 08:40AM	How Vistagen (VTGN) Stock Stands Out in a Strong Industry (Zacks)
Dec-27-23 08:30AM	Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.85%
Nov-11-23 01:03PM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:30PM	Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results (Business Wire) -6.17% -11.07%
Nov-08-23 08:30AM	Vistagen to Present at Stifel 2023 Healthcare Conference (Business Wire) -11.37%
Nov-07-23 08:30AM	Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences (Business Wire)
Nov-06-23 08:00AM	Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023 (Business Wire)
Oct-05-23 08:30AM	Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (Business Wire) -9.18%
Oct-02-23 07:30AM	Vistagen Announces Pricing of $100 Million Underwritten Offering (Business Wire) -19.85%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-12-23 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (Business Wire)
Sep-05-23 09:00AM	Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagens Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan (Business Wire)

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTGN

Vistagen Therapeutics Inc

Upgrade your FINVIZ experience